Research News
what's new
We translate the latest oncology research advances into language patients and families can understand. Every article ends with a disclaimer — information curation, not medical advice.
FDA Fast Track for Opamtistomig in First-Line Advanced Biliary Tract Cancer: Phase 3 Sentinel
The FDA has granted Fast Track designation to the PD-L1/4-1BB bispecific antibody opamtistomig for first-line treatment of advanced or metastatic biliary tract cancer. Early Phase 2 data show the combination with chemotherapy is well tolerated, with encouraging tumor shrinkage trends.
FDA Approves Pirtobrutinib for Treatment-Naive CLL/SLL, Phase 3 BRUIN CLL-313 Shows Substantial PFS Improvement
The FDA has approved pirtobrutinib for previously untreated CLL/SLL, with Phase 3 BRUIN CLL-313 showing significantly better progression-free survival than bendamustine plus rituximab; meanwhile, elinzanetant has received priority review for vasomotor symptoms caused by hormone therapy for breast cancer.
What's Next for the RAS Pathway After RMC-6236: G12D Inhibitors, Combination Therapy, and Opportunities for Hong Kong Patients
The approval of daraxonrasib is just the starting point of the RAS revolution. G12D-selective inhibitors, combination therapy strategies, and earlier lines of treatment are pushing the RAS field into its next phase.
RASolute 302 Phase 3 Data Analysis: RMC-6236 Doubles Overall Survival in Pancreatic Cancer
The Phase 3 RASolute 302 trial shows that the RAS(ON) inhibitor daraxonrasib extended median survival in previously treated metastatic pancreatic cancer from 6.7 months to 13.2 months, reducing the risk of death by 60%.
From 'Undruggable' to Precision Strike: The Latest Advances in KRAS G12C Inhibitors
Once considered 'undruggable,' KRAS has been transformed by the advent of G12C inhibitors. This article summarizes the latest clinical data on second-generation drugs and combination strategies.
RASONQUE Wins FDA Approval: First RAS(ON) Inhibitor daraxonrasib Rewrites Pancreatic Cancer Treatment History
On August 26, 2026, the FDA approved Revolution Medicines' RASONQUE (daraxonrasib, formerly RMC-6236) for previously treated metastatic pancreatic cancer, making it the first RAS-targeted drug in pancreatic cancer.
The Era of Precision Missiles: Applications of Antibody-Drug Conjugates (ADCs) in Breast Cancer Treatment
ADCs combine the precision of monoclonal antibodies with the killing power of chemotherapy drugs, and are rewriting treatment guidelines for HER2-positive, HER2-low, and even triple-negative breast cancer.
Who Is Suitable for Immunotherapy? Understanding Biomarkers That Predict Treatment Response
Immunotherapy does not work for everyone. How can biomarkers such as PD-L1, TMB, and MSI help doctors identify the patients most likely to benefit? This article explains in plain language.
When Targeted Therapy Stops Working: New Strategies for EGFR Lung Cancer Resistance
EGFR targeted therapy was a major breakthrough in lung cancer treatment, but resistance is almost inevitable. Fourth-generation inhibitors, bispecific antibodies, and combination therapies are opening new paths for patients.
Fighting Cancer with Your Own Immune Cells: The Current State of CAR-T Cell Therapy in Blood Cancers
CAR-T reprograms a patient's own T cells into cancer-fighting weapons and has created long-term remissions in lymphoma and leukemia. Here's a look at the current treatment landscape and future developments in Taiwan.
Is It Safe to Join a Clinical Trial? Understanding Participants' Rights and Protections
"Will I become a guinea pig?" is a common concern about clinical trials. This article explains the layers of protection, including informed consent forms, institutional review boards, and the right to withdraw.